JP2017523231A - 癌治療用アファチニブ医薬キット - Google Patents

癌治療用アファチニブ医薬キット Download PDF

Info

Publication number
JP2017523231A
JP2017523231A JP2017508542A JP2017508542A JP2017523231A JP 2017523231 A JP2017523231 A JP 2017523231A JP 2017508542 A JP2017508542 A JP 2017508542A JP 2017508542 A JP2017508542 A JP 2017508542A JP 2017523231 A JP2017523231 A JP 2017523231A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acid
group
weight
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017508542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523231A5 (enExample
Inventor
デトレフ モール
デトレフ モール
フロリアン ゾマー
フロリアン ゾマー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2017523231A publication Critical patent/JP2017523231A/ja
Publication of JP2017523231A5 publication Critical patent/JP2017523231A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017508542A 2014-08-15 2015-08-07 癌治療用アファチニブ医薬キット Pending JP2017523231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14181133 2014-08-15
EP14181133.1 2014-08-15
PCT/EP2015/068247 WO2016023822A1 (en) 2014-08-15 2015-08-07 Afatinib pharmaceutical kit for cancer treatment

Publications (2)

Publication Number Publication Date
JP2017523231A true JP2017523231A (ja) 2017-08-17
JP2017523231A5 JP2017523231A5 (enExample) 2018-09-20

Family

ID=51383563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508542A Pending JP2017523231A (ja) 2014-08-15 2015-08-07 癌治療用アファチニブ医薬キット

Country Status (4)

Country Link
US (2) US20160045436A1 (enExample)
EP (1) EP3180029A1 (enExample)
JP (1) JP2017523231A (enExample)
WO (1) WO2016023822A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5241273A (en) * 1975-09-23 1977-03-30 Johnson & Johnson Electrolyte mixture and drink
JP2004123642A (ja) * 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd 電解質組成物
JP2007510758A (ja) * 2003-11-12 2007-04-26 ストークリー−ヴァン キャンプ インコーポレイテッド 炭水化物及び電解質補充用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
CA2707424A1 (en) * 2007-11-28 2009-06-04 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2271214B1 (en) * 2008-03-28 2017-05-03 Particle Sciences, Inc. Pharmaceutical solutions and method for solubilizing therapeutic agents
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2616078B1 (en) * 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
US20120216909A1 (en) * 2010-11-01 2012-08-30 Abner Levy Dosing Adapter for Use with Oral Syringe
US9012464B2 (en) * 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
TWI605837B (zh) * 2011-01-27 2017-11-21 Kowa Co Ltd Pharmaceutical composition containing water-insoluble drug and pharmaceutical preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5241273A (en) * 1975-09-23 1977-03-30 Johnson & Johnson Electrolyte mixture and drink
JP2004123642A (ja) * 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd 電解質組成物
JP2007510758A (ja) * 2003-11-12 2007-04-26 ストークリー−ヴァン キャンプ インコーポレイテッド 炭水化物及び電解質補充用組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"テモダールカプセルを溶解して服薬する方法", くすりの参考資料, JPN6019020615, 2013, ISSN: 0004415013 *
テモダールカプセル添付文書, JPN6019020617, 2009, ISSN: 0004415014 *
兵庫県立病院薬剤部くすりの情報室, JPN6019020627, ISSN: 0004415018 *
医薬ジャーナル, vol. 42, no. 3, JPN6019020623, 2006, pages 961 - 968, ISSN: 0004415016 *
脳神経外科速報, vol. 17, no. 4, JPN6019020625, 2007, pages 487 - 490, ISSN: 0004415017 *
薬学雑誌, vol. 129, no. 3, JPN6019020620, 2009, pages 353 - 357, ISSN: 0004415015 *

Also Published As

Publication number Publication date
EP3180029A1 (en) 2017-06-21
WO2016023822A1 (en) 2016-02-18
US20160045436A1 (en) 2016-02-18
US20170319480A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
ES2391912T3 (es) Formulación en polvo del valganciclovir
US8263652B2 (en) Stabilized pediatric suspension of carisbamate
CN111683683A (zh) Pde v抑制剂的液体口服制剂
US20130150370A1 (en) Taste-masked pharmaceutical formulation having accelerated onset of action
JP2010513525A (ja) 安定な抗嘔吐経口噴霧製剤および方法
US20240156819A1 (en) Oral solution formulation
MXPA04009735A (es) Formulaciones liquidas de baja dosis de entecavir y uso.
JP2017523231A (ja) 癌治療用アファチニブ医薬キット
US20220160698A1 (en) Pharmaceutical oral liquid solution of ivacaftor
JP7614207B2 (ja) イブプロフェンおよびフェニレフリンを含んでなる液体組成物
US20230233470A1 (en) Formulations
CN114642633A (zh) 一种氨己烯酸制剂液体组合物
EP2558079B1 (en) Ciprofloxacin dry syrup composition
US20210213024A1 (en) Liquid compositions of aprepitant
JP2025517364A (ja) 汎ｒａｆキナーゼ阻害剤の経口液体懸濁液
JP2017523231A5 (enExample)
US20240091217A1 (en) Stable pharmaceutical oral liquid formulation of an antispasmodic agent
EP4108233A1 (en) Oral solution comprising a cinacalcet salt
WO2018002738A1 (en) Taste masked liquid pharmaceutical composition of (rs)-4-(ethyl[1-(4-methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate or pharmaceutically acceptable salts thereof
WO2013117793A1 (es) Composición farmacéutica sólida de cilostazol

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201224